Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDH1 | P12830 | 1/20 | 0.60 |
| ▸ | APC | P25054 | 1/20 | 0.60 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.60 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.60 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149547 | 0.93 | CDH1 (0.69) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL10211635 | 0.91 | KDM4E (0.59) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL1459138 | 0.90 | NAMPT (0.54) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL1458707 | 0.90 | NAMPT (0.54) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL9960774 | 0.90 | ALDH1A1 (0.57) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL1459040 | 0.90 | ALDH1A1 (0.57) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL10211177 | 0.88 | CDH1 (0.59) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL9953914 | 0.87 | CSNK2A2 (0.47) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL15383515 | 0.85 | CDH1 (0.65) | CDH1APCCTNNB1TCF7L2CSNK2A2 | |
| SCHEMBL5349000 | 0.84 | CSNK2A1 (0.56) | CSNK2A2CSNK2BKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661428-B1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2661428-B1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9469615-B2 | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469615-B2 | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2661428-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012087861-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087861-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | CDH1 2593/4885APC 2107/4885CTNNB1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.